Replimune Group (NASDAQ:REPL) Sets New 1-Year High – Should You Buy?

Shares of Replimune Group, Inc. (NASDAQ:REPL) reached a new 52-week high on Tuesday . The company traded as high as $15.83 and last traded at $15.8380, with a volume of 2126037 shares changing hands. The stock had previously closed at $14.71.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. upped their price objective on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday. Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $11.00 to $17.00 in a research report on Tuesday, August 4th. Finally, BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Replimune Group Stock Up 0.5%

The company has a current ratio of 5.23, a quick ratio of 5.23 and a debt-to-equity ratio of 1.00. The company has a 50-day simple moving average of $11.62 and a 200 day simple moving average of $8.23. The company has a market cap of $1.49 billion, a P/E ratio of -5.04 and a beta of 0.88.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). On average, equities analysts anticipate that Replimune Group, Inc. will post -2.94 EPS for the current year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 11,447 shares of Replimune Group stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,467.59. Following the completion of the sale, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. The trade was a 4.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 91,124 shares of company stock valued at $1,149,244 over the last 90 days. 5.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently bought and sold shares of REPL. AXQ Capital LP grew its stake in Replimune Group by 4.1% during the 2nd quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock valued at $300,000 after purchasing an additional 1,056 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Replimune Group by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock worth $157,000 after purchasing an additional 1,505 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Replimune Group by 4.7% in the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock worth $159,000 after purchasing an additional 1,712 shares during the last quarter. Ballentine Partners LLC lifted its holdings in shares of Replimune Group by 7.8% during the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock worth $230,000 after purchasing an additional 1,721 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after buying an additional 1,879 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.